lutetium-lu-177-dotatate has been researched along with Multiple-Endocrine-Neoplasia-Type-1* in 1 studies
1 other study(ies) available for lutetium-lu-177-dotatate and Multiple-Endocrine-Neoplasia-Type-1
| Article | Year |
|---|---|
Metastatic Insulinoma Controlled by Targeted Radionuclide Therapy With 177Lu-DOTATATE in a Patient With Solitary Kidney and MEN-1 Syndrome.
A 54-year-old man with multiple endocrine neoplasia type 1 had previous history of parathyroid surgery and left thyroid lobectomy 5 years earlier, and was referred for recurrent hypoglycemic episodes. Ga-DOTATATE PET/CT had showed multiple lesions in the right lung, liver, and pancreas. Biopsy from pancreas revealed low-grade neuroendocrine neoplasia. After 2 fractions of Lu-DOTATATE therapy, the size of lesions and its activity reduced on the Ga-DOTATATE scan and the hypoglycemic episodes manifested every day have scaled down to 1 time over 1-year follow-up. Herein, we report a case of malignant insulinoma successfully treated with radiolabeled somatostatin receptor therapy using Lu-DOTATATE. Topics: Antineoplastic Agents, Hormonal; Biopsy; Humans; Insulinoma; Male; Middle Aged; Multiple Endocrine Neoplasia Type 1; Octreotide; Organometallic Compounds; Pancreas; Pancreatic Neoplasms; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; Receptors, Somatostatin; Solitary Kidney | 2019 |